Results 161 to 170 of about 14,105 (264)

SPHINGOMYELIN

open access: yesJournal of Biological Chemistry, 1913
openaire   +1 more source

Metabolomic responses are more sensitive in muscle than serum following 28 days of arduous exercise with erythropoietin administration

open access: yesExperimental Physiology, Volume 111, Issue 5, Page 2613-2626, 1 May 2026.
Abstract Erythropoietin (EPO) administration stimulates haematological and non‐haematological adaptations that alter substrate oxidation and enhance aerobic performance. The effects of strenuous exercise and EPO on metabolites, and whether any effect is associated with haematological and non‐haematological adaptations, has not been assessed.
Devin J. Drummer   +11 more
wiley   +1 more source

Multi-omics data integration from patients with carotid stenosis illuminates key molecular signatures of atherosclerotic instability. [PDF]

open access: yesGenome Med
Das V   +14 more
europepmc   +1 more source

Association of Sphingolipids with All-Cause and Cardiovascular Death in Patients with Kidney Failure Treated with Maintenance Hemodialysis. [PDF]

open access: yesJ Am Soc Nephrol
Lidgard B   +10 more
europepmc   +1 more source

Distinct CSF lipidomic profiles are associated with five proteomic subtypes in patients with Alzheimer's disease. [PDF]

open access: yesMol Neurodegener Adv
Malliou G   +11 more
europepmc   +1 more source

Maternal Choline Supplementation in a Mouse Model of Down Syndrome and Alzheimer’s Disease Generates Unique Expression Profile Mosaics Within Three Hippocampal Excitatory Neuronal Populations

open access: yesThe FASEB Journal, Volume 40, Issue 7, 15 April 2026.
Maternal choline supplementation (MCS) is utilized in the Ts65Dn mouse model of Down syndrome (DS) and Alzheimer's disease (AD). At ~6 months of age, laser capture microdissection and single population RNA‐sequencing of three hippocampal neuron populations (CA1 and CA3 pyramidal neurons and dentate gyrus granule cells) were conducted.
Melissa J. Alldred   +8 more
wiley   +1 more source

Metabolomics reveals LysoPC a C17:0 (LPC 17:0) as candidate biomarker for personalized medicine in morbid obesity. [PDF]

open access: yesFront Med (Lausanne)
Stefanini E   +8 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy